
SDR2 Bundle 02
![]() |
Instruction |
![]() |
Time |
![]() |
Tasks |
The Fundamentals of GCRA
- Describe fundamentals of the genetic cancer risk assessment (GCRA) process
- Take a comprehensive cancer family history
- Explain the importance of and strategies for confirming key cancers
- Identify sporadic, familial, and hereditary cancer patterns
Documenting the Cancer Family History
- Recognize the importance of eliciting, documenting and verifying the patient family history
- Collect family history information, focusing on details and questions relevant to cancer history documentation
- Draw a 3-4 generation pedigree using standard pedigree nomenclature and symbols
- Demonstrate skills associated with proficiency in collecting and documenting the family history of cancers
Reading the Pathology Report through the Genomics Lens
- Apply reading and interpreting pathology reports to define cancer stage and extract information on histology/molecular features
- Describe the roles of other diagnostic data (imaging, CT scans, blood marker
Laboratory Methods for Inherited Cancer Susceptibilities
- Identify the methods, benefits, and limitations of different types of NGS cancer panels
- Recognize approaches to variant interpretation and reporting
- Apply understanding of different types of genetic tests to clinical vignettes
Characterization and Clinical Interpretation of Germline Genomic Variants
- Review types of genetic variants
- Outline the ACMG standards and guidelines for variant classification
- Describe the methods, resources, and tools used to classify variants
- Discuss approaches to re-classifying variants of uncertain significance (VUS)
Variant Nomenclature: Reading and Interpreting Genetic Test Results
- Recognize various types of genetic variants
- Distinguish between different types of variant nomenclature
- Interpret a genetic test report

Bita Nehoray, MS, CGC
Manager, Genetic Counselor
City of Hope
Bita Nehoray, MS, CGC, is a licensed board-certified genetic counselor specializing in cancer genetics. She received her Master’s degree in Human Genetics and Genetic Counseling from Stanford University. Ms. Nehoray joined the City of Hope Division of Clinical Cancer Genomics in 2012, where she provides cancer genetics services for patients and families suspected to have a hereditary predisposition to cancer, with a focus in Li-Fraumeni syndrome and clonal hematopoiesis of indeterminate potential. Current research projects include understanding cancer risk, penetrance, prevalence, and clinical outcomes for individuals with TP53 pathogenic variants as part of the LiFT UP study, evaluating the use of whole body MRI and liquid biopsy for early cancer detection, chatbot use for disclosure of germline genetic test results, and assessing community-based provider experiences with TP53 results on germline testing. She also serves on the genetic counseling advisory committee for the Li-Fraumeni Syndrome Association, the ClinGen TP53 Variant Curation Expert Panel, and the California Advisory Council for Sharsheret. She is faculty for the City of Hope Intensive Course in Genetic Cancer Risk Assessment. She is an active member of the National Society of Genetic Counselors and Southern California Genetic Counselors.

Colin Pritchard, MD, PhD
Assistant Professor
University of Washington
COLIN PRITCHARD, MD, PhD, is a Professor of Laboratory Medicine and Pathology at the University of Washington and Program Director for Cancer Precision Diagnostics for the Brotman Baty Institute for Precision Medicine. He also serves as the Co-Director of the Genetics and Solid Tumors Laboratory that services the Fred Hutchinson Cancer Center. The Pritchard laboratory focuses on oncology molecular diagnostics, particularly the source and utility of cell-free nucleic acid biomarkers in blood, and the development of innovative molecular diagnostics for the identification of DNA repair gene mutations that can guide therapeutic decision-making. His clinical work focuses on applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment. He has led the development and implementation of the ColoSeq™ Lynch and Polyposis Syndrome Panel and the UW-OncoPlex™ Cancer Gene Panel in current clinical use for cancer patients and their families. He is a longstanding distinguished faculty member of the City of Hope Clinical Cancer Genomics Community of Practice. In 2021 Dr. Pritchard was awarded the C2 Catalyst for Precision Medicine Award from Scientific American.

Sandra Dreike, MS, CGC
Manager, Genetic Counselor
City of Hope
SANDRA DREIKE, MS, CGC is a licensed board-certified genetic counselor who specializes in cancer genetics. Sandra joined the City of Hope Division of Clinical Cancer Genomics in 2019, where she provides genetic counseling and cancer genetic risk assessments as a Senior Genetic Counselor. She received her Master of Science degree is Genetic Counseling from University of California, Irvine and her bachelor’s degree in Biology from California Polytechnic State University, San Luis Obispo. She previously practiced as a genetic counselor in Honolulu, HI where she specialized in cancer genetics and general pediatric and adult genetics. In addition to patient care she is a faculty member of the City of Hope Intensive Course and Clinical Cancer Genomics Community of Practice, and research. Sandra is a member of the National Society of Genetic Counselors (NSGC) and Southern California Genetic Counselors (SCGC).

Elyssa Zukin, MS, CGC
Genetic Counselor
City of Hope
ELYSSA ZUKIN, MS, CGC is a licensed, board-certified genetic counselor specializing in cancer genetics at City of Hope National Medical Center. She has a Master of Science degree in genetic counseling from the University of California, Irvine, and a bachelor’s degree from the University of California, Los Angeles. Zukin joined City of Hope in 2020 as part of the Center for Precision Medicine. Her past research investigated the implications on clinical care when patients are found to carry genetic variants in genes associated with hereditary cancer syndromes that have conflicting interpretations by different genetics laboratories. She is a faculty member of the City of Hope Intensive Course and Clinical Cancer Genomics Community of Practice, and a member of the National Society of Genetic Counselors and the Southern California Genetic Counselors.

Madeline Currey
Clinical Research Associate
City of Hope
Madeline Currey is a clinical research associate in the Gray lab. She received a bachelor’s degree in biology from California State University Los Angeles, where she completed her undergraduate thesis in plant hydraulics and evolution. She joined the Gray lab in 2020, after a formative internship in the Division of Clinical Cancer Genomics. As an aspiring genetic counselor, she considers it an honor to be involved in research that increases the access and delivery of genetic services.